Clinical TrialsPeer Reviewed
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Authors (11)
Ming LuEli Lilly and Company, Indianapolis, Indiana.
Min Jung KimEli Lilly and Company, Indianapolis, Indiana.
Emily C CollinsEli Lilly and Company, Indianapolis, Indiana.
Sergey ShcherbininEli Lilly and Company, Indianapolis, Indiana.
JAMA neurology
Unknown
Published
Oct 13, 2025
Abstract
Abstract not available - data parsing issue resolved
Article Metrics
Sourcepubmed
Related Research
Explore more articles in this research category to discover related studies and findings.